



**AUSTRALIA**  
**Biotech**  
**Invest 2016**

Connecting Capital with Innovation

[www.australiabiotechinvest.com.au](http://www.australiabiotechinvest.com.au)

26 - 27  
October  
2016

Host Industry Body   Host State Partner   Major Partner

AusBiotech  
AUSTRALIA BIOTECHNOLOGY ORGANISATION

MELBOURNE  
Victoria  
Australia

100<sup>cs</sup>  
Just getting started

Melbourne Convention  
Centre, Victoria, Australia

### **Vectus Biosystems – Company overview**

Vectus Biosystems Ltd is a drug discovery and development company based in North Ryde, Sydney. Using their platform technology, Vectus has constructed a library of more than 200 small molecules with varying degrees of anti-hypertensive and/or anti-fibrotic properties.

Fibrosis, the formation of excess fibrous connective tissue in an organ, plays a role in an estimated 45 % of deaths in the US. This figure includes different diseases affecting the heart, lungs, kidney and liver, among others. While current treatments only slow the progression of fibrosis, Vectus has demonstrated in animal models that their compounds can reverse the process, leading to the restoration of normal tissue architecture.

To date, Vectus has identified drug targets with specific activity in the heart, kidney, lung and liver. The company's lead compound, VB0004 has potent anti-hypertensive properties, as well as anti-fibrotic activity in the heart and kidney. Vectus also aims to develop candidates for the treatment of fibrotic liver diseases, including nonalcoholic steatohepatitis (NASH) as well as pulmonary fibrotic diseases.